Your browser doesn't support javascript.
loading
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Martinez-Serra, Jordi; Del Campo, Raquel; Gutierrez, Antonio; Antich, Jose Luis; Ginard, Magdalena; Durán, Maria A; Bento, Leyre; Ros, Teresa; Amat, Juan C; Vidal, Carmen; Iglesias, Julio F; Orlinska, Izabela; Besalduch, Joan.
Afiliação
  • Martinez-Serra J; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
  • Del Campo R; Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain.
  • Gutierrez A; Department of Hematology, Hospital Son Llatzer, Palma de Mallorca, Spain.
  • Antich JL; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
  • Ginard M; Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain.
  • Durán MA; Department of Hematology, Clinica Rotger, Palma de Mallorca, Spain.
  • Bento L; Department of Hematology, Clinica Rotger, Palma de Mallorca, Spain.
  • Ros T; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
  • Amat JC; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
  • Vidal C; Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain.
  • Iglesias JF; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
  • Orlinska I; Department of Hematology, University Hospital Son Espases, Palma de Mallorca, Spain.
  • Besalduch J; Core of Sequentiation, University Hospital Son Espases, Palma de Mallorca, Spain.
Biomark Res ; 2: 14, 2014.
Article em En | MEDLINE | ID: mdl-25197554
ABSTRACT
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph'). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article